[{"id":"49dce72b-9d7c-4760-9f04-db0fc8e432e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06070012","created_at":"2023-10-06T14:11:25.919Z","updated_at":"2025-02-25T16:27:38.972Z","phase":"Phase 2","brief_title":"Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma","source_id_and_acronym":"NCT06070012","lead_sponsor":"Diwakar Davar","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" HLA-A*02:01","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-01-06"},{"id":"45804b31-abb5-4caf-bfa4-174bafa136c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535078","created_at":"2021-01-18T12:15:32.419Z","updated_at":"2025-02-25T15:06:47.576Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma","source_id_and_acronym":"NCT02535078","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • HLA-A*02:01 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Kimmtrak (tebentafusp-tebn)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 06/19/2023","primary_completion_date":" 06/19/2023","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2024-07-24"},{"id":"4f0f45d6-2518-42e6-9e5e-59562321231d","acronym":"TEBE-AM","url":"https://clinicaltrials.gov/study/NCT05549297","created_at":"2022-09-22T15:56:24.575Z","updated_at":"2024-07-02T16:35:15.907Z","phase":"Phase 2/3","brief_title":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","source_id_and_acronym":"NCT05549297 - TEBE-AM","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Kimmtrak (tebentafusp-tebn)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-03-07"},{"id":"3e8a0f3b-3463-4d31-a604-43157b0a68a9","acronym":"SCOPE","url":"https://clinicaltrials.gov/study/NCT04079166","created_at":"2021-01-18T19:58:29.386Z","updated_at":"2024-07-02T16:35:21.526Z","phase":"Phase 2","brief_title":"SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)","source_id_and_acronym":"NCT04079166 - SCOPE","lead_sponsor":"Scancell Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • SCIB1"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-01-31"},{"id":"075c8417-2b89-4c2c-8ef5-f6f96d59f609","acronym":"","url":"https://clinicaltrials.gov/study/NCT04960891","created_at":"2022-01-21T15:57:59.991Z","updated_at":"2024-07-02T16:36:18.183Z","phase":"","brief_title":"A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp","source_id_and_acronym":"NCT04960891","lead_sponsor":"Immunocore Ltd","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-01-21"},{"id":"04b39460-672d-4821-86d3-38c347aa3997","acronym":"","url":"https://clinicaltrials.gov/study/NCT01211262","created_at":"2021-01-18T04:51:40.484Z","updated_at":"2024-07-02T16:36:43.484Z","phase":"Phase 1","brief_title":"Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma","source_id_and_acronym":"NCT01211262","lead_sponsor":"Immunocore Ltd","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 09/28/2010","start_date":" 09/28/2010","primary_txt":" Primary completion: 02/16/2016","primary_completion_date":" 02/16/2016","study_txt":" Completion: 02/16/2017","study_completion_date":" 02/16/2017","last_update_posted":"2020-07-08"}]